证券之星消息，8月12日通用设备板块较上一交易日下跌0.05%，奔朗新材领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。通用设备板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301018 | 申菱休境 | 56.02 | 13.13% | 28.32万 | | 15.63亿 | | 603757 | 大元泉业 | 35.41 | 10.00% | 6.15万 | | 2.17亿 | | 603090 | 宏盛股份 | 35.35 | 9.99% | 7.41万 | | 2.55亿 | | 300990 | 同飞股份 | 68.41 | 8.38% | 8.82万 | | 5.84亿 | | 300430 | 诚益通 | 22.86 | 6.87% | 46.15万 | | 10.46 乙 | | 688448 | 磁容科技 | 43.67 | 6.25% | 8.88万 | | 3.65亿 | | 0 ...

Group 1 - The company has established a dual-track strategy focusing on both "invasive and non-invasive" approaches in the brain-computer interface (BCI) sector [1] - In the non-invasive serious medical field, the company is integrating existing rehabilitation equipment with brain-computer interfaces to enhance product functionality and is actively promoting commercialization [1] - Beyond the medical field, the company is exploring applications in "non-medical" scenarios, including education, elderly care, and health, having launched a BCI biofeedback system aimed at attention detection and training in the education sector [1] Group 2 - In the invasive field, the company is constructing a BCI technology research verification center and an animal testing center, which are crucial for its strategic layout in the BCI domain [1] - These two centers will create a complete innovation chain from "basic research - technology verification - achievement transformation" [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by recent policy support and technological advancements, with several companies in the field seeing substantial stock price increases. Group 1: Company Performance - QiSheng Technology (麒盛科技) saw its stock price rise by 10.01% to 14.40, with a market capitalization of 5.08 billion, focusing on sleep-related technologies and brain-machine interaction [2] - Innovation Medical (创新医疗) increased by 9.99% to 20.59, with a market cap of 8.57 billion, holding a 40% stake in BoLing Brain-Machine Technology, which is developing core BCI technologies [2] - Xiangyu Medical (翔宇医疗) surged by 13.72% to 65.97, with a market cap of 10.56 billion, having completed several key projects in the BCI field and holding numerous patents [2] - Chengpin Technology (诚品通) rose by 8.60% to 23.23, with a market cap of 6.04 billion, collaborating with Tsinghua University on both non-invasive and invasive BCI technologies [2] Group 2: Industry Developments - On August 7, the Ministry of Industry and Information Technology and six other departments released guidelines to promote BCI innovation, aiming for breakthroughs in key technologies by 2027 [3] - The establishment of the Hubei BCI Industry Innovation Development Alliance was announced on August 9, indicating a collaborative effort to advance the sector [3] - The 2025 World Robot Competition showcased non-invasive BCI products for nerve injury treatment, highlighting the practical applications of BCI technology [3] Group 3: Institutional Insights - The guidelines emphasize the establishment of an advanced technology, industry, and standard system for BCI by 2027, with expectations for BCI applications in healthcare, rehabilitation, and skill replacement [4] - BCI technology is positioned at the intersection of life sciences and information sciences, facilitating collaboration between biological and machine intelligence [4] - Various provinces and cities in China are implementing policies to support BCI development, with significant potential for commercialization in healthcare and other sectors [5]

Core Viewpoint - The company has established a dual-track strategy of "invasive and non-invasive" approaches in its business operations [1] Non-Invasive Medical Sector - The company is currently integrating existing rehabilitation equipment with brain-computer interface (BCI) technology to enhance product functionality and is actively promoting commercialization [1] - Beyond the medical field, the company is exploring applications in "non-medical" scenarios, including education, elderly care, and health [1] - In the education sector, the company has launched a BCI biofeedback system aimed at attention detection and training [1] Invasive Medical Sector - The company is constructing a brain-computer interface technology research and validation center along with an animal testing center, which are crucial for its strategic layout in the BCI field [1] - These two centers will create a complete innovation chain from "basic research - technology validation - achievement transformation" [1]

Group 1 - The A-share market has seen a strong performance in brain-computer interface concept stocks, with notable increases in share prices for several companies [1] - Major gainers include Mailland, which rose nearly 18%, and Xiangyu Medical, which increased over 10% [1] - Other companies such as Qisheng Technology and Innovation Medical reached their daily limit up of 10%, while Chengyitong and Sanbo Brain Science rose over 8% [1] Group 2 - Detailed stock performance includes: - Mailland (688273) with a 17.99% increase and a market cap of 5.28 billion, year-to-date increase of 129.09% [2] - Xiangyu Medical (688626) with a 10.33% increase and a market cap of 10.2 billion, year-to-date increase of 119.06% [2] - Qisheng Technology (603610) with a 10.01% increase and a market cap of 5.083 billion, year-to-date increase of 15.14% [2] - Innovation Medical (002173) with a 9.99% increase and a market cap of 9.086 billion, year-to-date increase of 158.67% [2] - Chengyitong (300430) with an 8.37% increase and a market cap of 6.329 billion, year-to-date increase of 51.81% [2] - Sanbo Brain Science (301293) with an 8.19% increase and a market cap of 12.8 billion, year-to-date increase of 43.94% [2] - Aipeng Medical (300753) with a 6.54% increase and a market cap of 4.601 billion, year-to-date increase of 107.58% [2] - Weisi Medical (688580) with a 5.91% increase and a market cap of 5.376 billion, year-to-date increase of 104.65% [2] - Lepu Medical (300003) with a 5.61% increase and a market cap of 34.4 billion, year-to-date increase of 62.75% [2]

Group 1 - The brain-computer interface sector is experiencing a significant rise, with several companies showing strong performance [1] - Innovative Medical has reached its daily limit increase, indicating strong investor interest and confidence [1] - Qi Sheng Technology previously hit its limit up, reflecting positive market sentiment towards the company [1] Group 2 - Companies such as Xiangyu Medical, Mcland, and Beiyikang have all seen their stock prices increase by over 10%, showcasing a broader trend of growth in the sector [1] - Other companies including Aipeng Medical, Chengyitong, Sanbo Brain Science, Weisi Medical, and Lihua Science and Technology are also experiencing upward movement in their stock prices [1]

人民财讯8月12日电，诚益通（300430）8月12日在互动平台表示，公司已确立"侵入式与非侵入式"双轨 并行的战略布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级 现有产品功能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用， 包括教育、养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口 生物反馈系统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司 在脑机接口领域的重要战略布局，两大中心将构建"基础研究—技术验证—成果转化"的完整创新链条。 ...

诚益通（300430.SZ）8月12日在投资者互动平台表示，公司已确立"侵入式与非侵入式"双轨并行的战略 布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级现有产品功 能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用，包括教育、 养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口生物反馈系 统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司在脑机接口 领域的重要战略布局，两大中心将构建"基础研究-技术验证-成果转化"的完整创新链条。 每经AI快讯，有投资者在投资者互动平台提问：请问公司下属脑连科技的bci脑控机器人相关开发进度 如何？有哪些储备技术和产品？ （文章来源：每日经济新闻） ...

风险提示：股市有风险，投资需谨慎。 来源：金融界 8月11日早盘时段，诚益通曾出现快速回调，在五分钟内跌幅超过2%，最低触及20.81元。但随后股价 逐步回升，最终实现小幅收涨。当日主力资金净流出3962.14万元，近五个交易日累计净流出9877.52万 元。 截至8月11日收盘，诚益通报21.39元，较前一交易日上涨0.04元。当日成交量为305876手，成交金额达 6.57亿元，振幅为5.71%。 诚益通属于通用设备制造行业，主营业务涵盖智能制造和生物医疗两大领域。公司产品包括自动化控制 系统、医疗康复设备等，在北京地区具有业务布局。作为合成生物概念股，公司还涉及专精特新等创新 领域。 ...

Group 1 - The brain-computer interface (BCI) concept stocks have been active, with multiple stocks rising significantly, and several exceeding 100% increase in price year-to-date [1][3][4] - A recent policy document issued by seven government departments aims to accelerate the BCI industry's development, proposing 17 specific measures to enhance hardware and software capabilities, application of technological achievements, and support for innovation [2][4] - The document outlines a roadmap for BCI development, with milestones set for 2025 and 2027, including the establishment of a comprehensive support system and the cultivation of leading enterprises [5][6] Group 2 - The policy encourages various application scenarios, including industrial manufacturing, healthcare, and consumer applications, aiming to break down departmental barriers and enhance collaboration across the industry [7][8] - The BCI industry is transitioning from research to commercialization, with significant advancements in non-invasive technologies and ongoing efforts to develop core components domestically [8][9] - The medical sector is identified as the fastest-growing area for BCI commercialization, with a projected global market size of $40 billion by 2030, driven by the treatment of central nervous system diseases [9][10] Group 3 - Recent developments include the establishment of pricing for BCI medical services, with specific costs outlined for invasive and non-invasive procedures, providing a foundation for clinical application [12][13] - Several listed companies are actively engaging in the BCI sector, with ongoing research and product development in invasive and semi-invasive BCI applications [13][15] - Companies are also preparing to establish funds and partnerships to support innovation and investment in the BCI field, indicating a strong interest in the sector's growth [14][15]